| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| ADC Therapeutics SA | Chief Legal Officer | Common Shares | 359,034 | $1,181,221 | $3.29 | 06 Dec 2025 | Direct |
| ANTARES PHARMA, INC. | EVP, General Counsel, Chief Compliance Officer and Secretary | Common Stock | 0 | $5.60 | 24 May 2022 | Direct | |
| ANTARES PHARMA, INC. | EVP, General Counsel, Chief Compliance Officer and Secretary | Stock Option (right to buy) | 0 | 24 May 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| ADCT | ADC Therapeutics SA | 06 Dec 2025 | 1 | -$162,881 | 4 | Chief Legal Officer | 09 Dec 2025, 17:09 |
| ADCT | ADC Therapeutics SA | 13 Feb 2025 | 1 | +$354,200 | 4 | Chief Legal Officer | 14 Feb 2025, 18:23 |
| ADCT | ADC Therapeutics SA | 06 Dec 2024 | 1 | -$129,764 | 4 | Chief Legal Officer | 09 Dec 2024, 20:35 |
| ADCT | ADC Therapeutics SA | 02 Jan 2024 | 0 | $0 | 3 | Chief Legal Officer | 02 Jan 2024, 20:08 |
| ATRS | ANTARES PHARMA, INC. | 24 May 2022 | 10 | -$4,148,721 | 4 | EVP, General Counsel, Chief Compliance Officer and Secretary | 26 May 2022, 17:25 |
| ATRS | ANTARES PHARMA, INC. | 03 Mar 2022 | 2 | -$51,813 | 4 | EVP General Counsel, Secretary | 04 Mar 2022, 17:34 |
| ATRS | ANTARES PHARMA, INC. | 16 Feb 2022 | 2 | -$48,674 | 4 | EVP General Counsel, Secretary | 18 Feb 2022, 18:19 |
| ATRS | ANTARES PHARMA, INC. | 10 Jun 2021 | 4 | +$211,791 | 4 | EVP General Counsel, Secretary | 14 Jun 2021, 18:21 |
| ATRS | ANTARES PHARMA, INC. | 08 Jun 2021 | 1 | -$70,222 | 4 | EVP General Counsel, Secretary | 10 Jun 2021, 17:38 |